the Impact of Paediatric Use of Proton Pump Inhibitors on the Risk of Community Acquired Infections.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

290286 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-03-31

Study Completion Date

2017-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pharmacological treatment of physiologic Gastro-esophageal Reflux disease (GERD) is excessive in France, as 65%-85% of children below 11 years are being treated, frequently with Proton Pump Inhibitors (PPIs) PPI have been associated, in adults, with an increase of infection rate but data in pediatry are scarce, especially in community medecine. Recently a study conducted in England brought up controversial results suggesting that the use of PPIs can be associated with a reduced risk of community acquired pneumonia.

Our study was aimed to assess, on a population-based database, the association between PPI prescription and community infections in children of 11 years or under.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)

NCT00300755

Gastroesophageal Reflux

COMPLETED PHASE3

Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)

NCT00365300

Gastroesophageal Reflux

COMPLETED PHASE3

The Gastrointestinal Microbiome of Infants With GERD and PPI Therapy: a Pilot Study

NCT02359604

Gastroesophageal Reflux

COMPLETED NA

Longitudinal Study of Children With a Chronic Cough and the Impact of Gastroesophageal Reflux

NCT00771706

Cough Gastroesophageal Reflux

WITHDRAWN PHASE3

The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux

NCT00324974

Gastroesophageal Reflux Disease

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Community Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PPI exposed children

all children with at least one prescription of PPI

Intervention Type OTHER

all children with at least one prescription of PPI

non-exposed children

all children with no prescription of PPI

Intervention Type OTHER

all children with no prescription of PPI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

all children with at least one prescription of PPI

Intervention Type OTHER

all children with no prescription of PPI

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children aged 11 years or below with at least 2 consultations during the follow up

Exclusion Criteria

* chronic pulmonary or cardiac
* muscoviscidosis
* immunodeficiency
* H. pylori infection
* Diabetes
* Denutrition
* known digestive upper tract malformation

Maximum Eligible Age

11 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No